Will a boom in genetic testing of tumors be a boon for Soon-Shiong?
Cancer patients across the country are increasingly being tested for “microsatellite instability,” or MSI status — characterized by a set of genetic markers that can help doctors identify the most effective treatment.
In this boom, Dr. Patrick Soon-Shiong has spotted a business opportunity.
The biotech billionaire has been struggling to find a market for his pricey diagnostic test, GPS Cancer, which recommends treatments based on an analysis of tumor genetics.
